Providers support approvals of therapies for prostate cancer, lymphoma, heart disease
Click Here to Manage Email Alerts
Key takeaways:
- The analysis revealed strong support for FDA approvals of glofitamab-gxbm for lymphoma and talazoparib for prostate cancer.
- Some HCPs were hesitant about the first gene therapy for Duchenne muscular dystrophy.
An analysis of online conversations among health care professionals on social media in June revealed overwhelming support for FDA approvals of therapies for prostate cancer and lymphoma.
Health care professionals (HCPs) on social media also spoke favorably about approval of a drug intended to reduce cardiovascular events. They offered mixed reaction to FDA approval of a therapy for children with Duchenne muscular dystrophy.
Image: Creation Healthcare
Creation Healthcare — a leading health care insights consultancy — used CREATION Pinpoint to analyze 2,817 Twitter posts generated by 1,949 HCPs to identify key aspects of the discussions about FDA approvals of pharmaceutical products from June 1 through June 30.
They studied HCPs’ reactions and thoughts surrounding several product approvals to discover which new product launches they are discussing, as well as #WhatHCPsThink.
The data included mentions of drug approvals by the FDA, European Medicines Agency, National Institute for Health and Care Excellence, and the Committee for Medicinal Products for Human Use, as well as mentions of drug approvals by HCPs in their Twitter conversations.
On June 15, the FDA granted accelerated approval to glofitamab-gxbm (Columvi, Genentech) for treatment of relapsed or refractory diffuse large B-cell lymphoma or large B-cell lymphoma arising from follicular lymphoma.
HCPs called the day a historical one for DLBCL and were rather excited about the treatment. They described it as “great news for patients” and hoped it would be approved in other countries soon.
On June 20, the FDA approved talazoparib (Talzenna, Pfizer) for use in combination with enzalutamide (Xtandi; Astellas, Pfizer) to treat homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.
Talazoparib — an oral poly(ADP-ribose) polymerase (PARP) inhibitor — already had been approved to treat certain adults with breast cancer.
Analysis of online conversations among HCPs on social media revealed significant support for approval of the prostate cancer indication. HCPs commented on the remarkable results of the clinical trial that led to the approval, and labeled it as a significant leap forward in prostate cancer treatment.
Also on June 20, the FDA approved colchicine (Lodoco, AGEPHA Pharma), the first anti-inflammatory drug for reducing cardiovascular events among adults who have established atherosclerotic cardiovascular disease (ASCVD). Research showed the drug reduced risk for cardiac events by an additional 31%.
A small number of HCPs expressed concern about the possibility of a price increase for generic colchicine. However, overall, HCPs were quick to recommend the new treatment online as an effective option, calling the approval “a new era” in residual inflammatory ASCVD risk.
On June 22, the FDA approved the first gene therapy for pediatric patients aged 4 or 5 years with Duchenne muscular dystrophy.
The approval of delandistrogene moxeparvovec-roki (Elevidys, Sarepta Therapeutics) initially was met with mixed responses from HCPs.
Some were on the fence about the accelerated approval in light of limitations in trial results, leading a few clinical professionals to disagree with the FDA’s decision. However, several HCPs also were enthusiastic about the approval, with some calling it a “groundbreaking” treatment.
References:
- FDA approves Genentech’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma. Available at: https://www.gene.com/media/press-releases/14994/2023-06-15/fda-approves-genentechs-columvi-the-firs. Published June 15, 2023. Accessed July 14, 2023.
- FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer (press release). Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate. Published June 20, 2023. Accessed July 14, 2023.
- U.S. FDA approves first anti-inflammatory drug for cardiovascular disease (press release). Available at: https://www.businesswire.com/news/home/20230620113838/en/U.S.-FDA-Approves-First-Anti-Inflammatory-Drug-for-Cardiovascular-Disease. Published June 20, 2023. Accessed July 14, 2023.
- FDA approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy (press release). Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy. Published June 22, 2023. Accessed July 14, 2023.
Collapse
Click Here to Manage Email Alerts